A Real-world Study of DEXYCU in the Treatment of Inflammation After Cataract Surgery

PHASE4CompletedINTERVENTIONAL

Enrollment

263

Participants

Timeline

Start Date

October 28, 2021

Primary Completion Date

July 8, 2023

Study Completion Date

December 14, 2023

Conditions

InflammationCataract

Interventions

DRUG

Dexycu

single injection,5ul solution,concentration: 103.4 μg/μl, equivalent to 517μg dexamethasone

Trial Locations (2)

Hainan Traditional Chinese Medicine Hospital, Haikou

Boao Super Hospital, Bo'ao

All Listed Sponsors

lead

Ocumension Therapeutics (Shanghai) Co., Ltd

INDUSTRY

NCT06497699 - A Real-world Study of DEXYCU in the Treatment of Inflammation After Cataract Surgery | Biotech Hunter | Biotech Hunter